Trofinetide’s classification as “Speculative” despite achieving the highest peptide ranking reflects a complete absence of Alzheimer’s-disease-specific experimental data, with therapeutic hypothesis derived exclusively from network proximity to IGF1 pathway genes, without mechanistic confirmation or demonstration of efficacy in transgenic AD mice. This evidence concerns the gene IGF1 and Alzheimer disease.